Efficacy and safety of sumatriptan plus naproxen sodium in the acute treatment of migraine: Systematic review and meta-analysis of randomized controlled trials

Internet Journal of Pain, Symptom Control and Palliative Care

Volumn 8, Issue 2, 2011, Pages

  Suthisisang, Chuthamanee C ^a   Poolsup, Nalinee ^b   Suksomboon, Naeti ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SILPAKORN UNIVERSITY   (Thailand)

Author keywords

Meta analysis; Migraine; Naproxen sodium; Sumatriptan; Systematic review

Indexed keywords

EID: 80052998286     PISSN: 15288277     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Headache Classification Committee for the International Headache Society. The international classification of headache disorders: second edition. Cephalalgia; 2004; 24(Suppl 1):1-151.
2. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache; 2005; 45(Suppl 1):S3-S13.
3. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache; 2008; 48:553-63.
4. Landy S. Migraine throughout the life cycle. Treatment through the ages. Neurology; 2004; 62(Suppl 2):S2-S8.
5. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute treatment of migraine. Lancet Neurol; 2010; 9:285-98.
6. Goadsby PJ. The pharmacology of headache. Prog Neurobiol; 2000; 65:509-25.
7. Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache; 2007; 47:1169-1177.
8. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache; 2008; 48:236-247.
9. Ashcroft DM, Millson D. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf; 2004; 13:73-82.
10. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol; 2007; 254:705-12.
11. Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache; 2010; 50:808-818.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials; 1996; 17:1-12.
13. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trial. Stat Med; 1991; 10:1665-1677.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials; 1986; 7: 177-188.
15. Higgin JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ; 2003; 327:557-560.
16. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr; 2000; 58:428-430.
17. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache; 2005; 45:983-991.
18. Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA; 2007; 297:1443-1454.
19. Landy S, DeRossett SE, Rapoport A, Rothrock J, Ames MH, McDonald SA, Burch SP. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. MedGenMed; 2007; 9:53.
20. Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH, McDonald SA, Lener SE, Toso C. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology; 2008; 71:114-121.
21. Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD, Nelsen AC. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia; 2009; 29:826-36.
22. Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, Derosier FJ, McDonald SA. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol; 2009; 114:106-13.
23. Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache; 2009; 49:971-82.
24. Durham PL, Vause CV, Derosier F, McDonald S, Cady R, Martin V. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache; 2010; 50:844-851.
25. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia; 2000; 20:765-786.
26. Jenkins DW, Feniuk W, Humphrey PP. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol; 2001; 134:1296-1302.
27. Moskowitz MA, Cutrer FM. Sumatriptan: A receptor-targeted treatment for migraine. Annu Rev Med; 1993; 44:145-154.
28. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain; 2001; 89:107-110.
29. Burstein R, Jakubowski M. Implications of multimechanism therapy: When to treat? Neurology; 2005; 64(Suppl. 2):S16-S20.
30. Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: Blockade by intravenous naproxen infusion. Neuroscience; 2007; 148:573-583.
31. Lacey LF, Hassey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol; 1995; 47:543-8.
32. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia; 2002; 22:633-58.
33. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia; 1996; 16:264-269.
34. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache; 2004; 44:414-425.
35. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ; 1997; 315:629-634.